Indian pharma stocks have been one of the more interesting corners of the stock market lately. While several other sectors wobbled through bouts of volatility in early 2026, pharmaceutical companies largely held their ground ...
Moderna flu vaccine moved a step closer to market approval after an independent panel of advisers to the US Food and Drug Administration (FDA) unanimously backed the company's experimental shot for adults aged 50 years and older.
India’s pharma market shows balanced growth as rising volumes, steady pricing, and new launches drive sustained expansion across therapies and regions.
Bajaj healthcare expansion is gaining momentum as Bajaj Integrated Health System (BIHS) joins hands with Philips India to strengthen connected healthcare delivery across the country.
A Rs 500 crore AI healthcare hub is set to transform Telangana as Hyderabad-based Pulsus Group announced a major investment to expand its presence in the state's healthcare and technology ecosystem.
India has gained access to a globally acclaimed prostate cancer therapy with the launch of Pluvicto by Novartis.The company announced the introduction of Pluvicto in India for eligible patients with advanced prostate cancer, marking...
Sagility's AI growth strategy received a major boost after the healthcare services provider announced the acquisition of U.S.-based CareSeed, a company known for its healthcare quality analytics and HEDIS reporting solutions.
India must stay attractive for innovation-led pharma investment as policy, IP protection and faster approvals remain critical to drive next-gen therapies and global clinical research.
The Navi Mumbai MediCity project has taken a major step forward with the Maharashtra government signing a Memorandum of Understanding (MoU) with Cleveland Clinic, Brookfield Asset Management, and Arodhan Health City.
Global race for generic semaglutide gains pace ahead of patent expiry, with Hetero-Richter partnership highlighting rising competition and export opportunities for India.